Phase II study of Bria-IMT in metastatic breast cancer [Video]

Carmen van Dooijeweert, MD, PhD, UMC Utrecht, Utrecht, Netherlands, talks on the Phase II CONFIDENT-B trial – a single center, prospective study looking to which extent an artificial intelligence (AI)-assisted clinical workflow for the detection of sentinel lymph node metastases reduced immunohistochemistry use, while maintaining current diagnostic safety standards. The study showed that AI-implementation for the detection of sentinel node metastases led to a significant reduction in immunohistochemistry use – with significant cost savings and saving pathologists’ time. The study also reported that patients were not at risk of an inferior diagnosis. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.